)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
KALA BIO
KALA BIO (KALA) investor relations material
KALA BIO AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2026 summary3 Nov, 2026
Opening remarks and agenda
Meeting called to order after confirmation of a quorum; five agenda items were presented, and polls opened for electronic voting.
Proxy materials were made available on September 24, 2026, to stockholders of record as of September 10, 2026.
Board and executive committee updates
Yonatan Colman and Brendan Purdy were nominated as Class III directors, with terms running until the 2029 annual meeting if elected.
Shareholder proposals
Proposals sought approval of executive compensation on a non-binding advisory basis, ratification of HTL International, LLC as auditor for FY ended December 31, 2026, and authorization for a 1-for-2 to 1-for-300 reverse stock split at the board’s discretion.
A fifth proposal sought authority to adjourn or postpone the meeting if needed to continue soliciting votes; the board recommended support if necessary.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from KALA BIO
- Stockholders will vote on director elections, executive pay, auditor ratification, and a reverse stock split.KALA
Proxy filing - Stockholders will vote on director elections, compensation, auditor, and a reverse stock split.KALAProxy filing
- Net loss narrowed sharply as focus shifted to AI platform, with liquidity supported by note receivable.KALAQ2 2026
- Pivoting to AI platform services for biotech, with $350M shelf registration and recent restructuring.KALARegistration filing
- Q1 2026 net loss fell to $1.6M as focus shifted to AI platform and cost reductions.KALAQ1 2026
- Pivoting to AI for biotech, offering $350M in securities amid high strategic and execution risk.KALARegistration filing
- Transitioned to AI platform development after clinical failure, with narrowed losses and ongoing liquidity risks.KALAQ4 2025
- Registering 241M+ shares for resale amid Nasdaq compliance risks and leadership changes.KALARegistration Filing
- KPI-012's phase II-B trial for PCED targets a major unmet need, with data expected Q1 2025.KALAH.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Next KALA BIO earnings date
Q3 202619 Nov, 2026
KALA BIO
Next KALA BIO earnings date
Q3 202619 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
KALA BIO Inc. (formerly Kala Pharmaceuticals Inc.) is a biopharmaceutical company focused on developing and commercializing innovative treatments for ocular diseases. The company leverages its proprietary AMPPLIFY drug delivery technology, which enhances the penetration of therapeutic agents into target tissues. KALA BIO’s product portfolio includes treatments for conditions such as dry eye disease, ocular inflammation, and other front-of-the-eye disorders. The company is headquartered in Arlington, Massachusetts, and its shares are listed on the NASDAQ.